A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
NCT06255704
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Mantle Cell Lymphoma
Interventions
DRUG:
Zanubrutinib and RCHOP/RDHAP
Sponsor
Shanxi Province Cancer Hospital